Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive ...
Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danzitenâ„¢, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...
Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
Transcription activation of genes by estrogens is driven by enhancers, which are often located within the same Topologically Associating Domain (TAD) as non-targeted promoters. We investigated how ...
Researchers sought to determine whether combination decitabine, venetoclax, and ponatinib would be effective in patients with accelerated phase CML.
A research team has successfully sequenced and assembled the genomes of all four Macadamia species, marking a significant ...
If approved, donidalorsen would be a first-in-class RNA-targeted medicine for hereditary angioedema. The agency’s goal date ...
In conclusion, this intriguing report builds on the work of many other groups by further unraveling MECP2 function in the ...
The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...
ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback